Cognition Therapeutics (CGTX) Price & Analysis

Compare

572 Followers

CGTX Stock Chart & Stats

$1.66

-$0.03(-3.56%)

At close: Jan 08 4:00 PM EST

$1.66

-$0.03(-3.56%)

Day’s Range― - ―

52-Week Range$0.22 - $3.83

Previous CloseN/A

Volume950.02K

Average Volume (3M)2.91M

Market Cap

$138.51M

Enterprise Value$8.64M

Total Cash (Recent Filing)$39.33M

Total Debt (Recent Filing)$380.00K

Price to Earnings (P/E)―

Beta2.04

Next Earnings

Apr 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding88,223,885

10 Day Avg. Volume2,171,776

30 Day Avg. Volume2,911,286

Financial Highlights & Ratios

PEG Ratio0.71

Price to Book (P/B)1.49

Price to Sales (P/S)0.00

P/FCF Ratio-0.98

Enterprise Value/Market Cap0.06

Enterprise Value/Revenue34.57

Enterprise Value/Gross Profit-48.83

Enterprise Value/Ebitda-0.25

Forecast

1Y Price Target

$3.00

Price Target Upside80.72% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Breakthrough Therapy DesignationThe expected decision on Breakthrough Therapy Designation for zervimesine in dementia with Lewy bodies could be a key catalyst for the stock.

Clinical DevelopmentZervimesine has shown substantial promise in dementia with Lewy bodies, with clinically meaningful impacts and a significant slowing of neuropsychiatric symptoms.

Regulatory FeedbackFavorable FDA feedback on zervimesine's clinical pathway in Alzheimer's disease is a significant step forward for Cognition Therapeutics.

Bears Say

Cognition Therapeutics News

Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)

“The $30 million registered direct offering enables us to begin preparations for the next stage of development for...

2d ago

CGTX

Cognition Therapeutics Advances Alzheimer’s Drug Development

Cognition Therapeutics, Inc. ( ($CGTX) ) has released its Q3 earnings. Here is a breakdown of the information...

1d ago

CGTX

Cognition Therapeutics Advances Zervimesine to Phase 3 Trials

Cognition Therapeutics ( ($CGTX) ) has shared an update. Cognition Therapeutics is advancing its lead product candidate, zervimesine,...

2M ago

CGTX

Cognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollment

Cognition Therapeutics (CGTX) announced that the Phase 2 ‘START’ Study has reached the 75% enrollment mark. The START...

2M ago

CGTX

Cognition Therapeutics Announces $30.1M Direct Offering

Cognition Therapeutics ( ($CGTX) ) has issued an update. On August 27, 2025, Cognition Therapeutics, Inc. announced it...

2M ago

CGTX

Cognition Therapeutics announces $30M registered direct offering of common stock

Titan Partners Group, a division of American Capital Partners, is acting as the sole placement agent for the...

2M ago

CGTX

Cognition Therapeutics Regains Nasdaq Compliance

Cognition Therapeutics ( ($CGTX) ) has issued an update. Cognition Therapeutics, Inc. received a deficiency letter from Nasdaq...

2M ago

CGTX

Cognition Therapeutics regains compliance with Nasdaq

Cognition Therapeutics (CGTX) was notified by Nasdaq that the company has regained compliance with the exchange’s continued listing...

2M ago

CGTX

Cognition Therapeutics Reports Q2 2025 Financial Results

Cognition Therapeutics, Inc. ( ($CGTX) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

CGTX

Cognition Therapeutics confirms aligment with FDA on path for zervimesine

Cognition Therapeutics (CGTX) received final minutes from the FDA pertaining to the end-of-Phase 2 meeting that was conducted...

3M ago

CGTX

Promising Developments and Regulatory Milestones Drive Buy Rating for Cognition Therapeutics

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cognition Therapeutics and keeping the price target...

3M ago

CGTX

Cognition Therapeutics reports Q2 EPS (11c), consensus (10c)

“The second quarter of 2025 has been very productive, with milestones from each of our clinical programs,” stated...

3M ago

CGTX

Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors

Cognition Therapeutics, Inc. (($CGTX)) announced an update on their ongoing clinical study. The recent clinical study update from...

3M ago

CGTX

Cognition Therapeutics presents data at AAIC on CT1812 in dementia

Cognition Therapeutics (CGTX) presented results from the Phase 2 COG1201 SHIMMER study of zervimesine, CT1812, in dementia with...

3M ago

CGTX

CGTX FAQ

What was Cognition Therapeutics’s price range in the past 12 months?

Cognition Therapeutics lowest stock price was $0.22 and its highest was $3.83 in the past 12 months.

What is Cognition Therapeutics’s market cap?

Cognition Therapeutics’s market cap is $138.51M.

When is Cognition Therapeutics’s upcoming earnings report date?

Cognition Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 144 days.

How were Cognition Therapeutics’s earnings last quarter?

Cognition Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.063 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.027.

Is Cognition Therapeutics overvalued?

According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cognition Therapeutics pay dividends?

Cognition Therapeutics does not currently pay dividends.

What is Cognition Therapeutics’s EPS estimate?

Cognition Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cognition Therapeutics have?

Cognition Therapeutics has 88,223,885 shares outstanding.

What happened to Cognition Therapeutics’s price movement after its last earnings report?

Cognition Therapeutics reported an EPS of -$0.063 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went down -1.775%.

Which hedge fund is a major shareholder of Cognition Therapeutics?

Among the largest hedge funds holding Cognition Therapeutics’s share is Carlson Capital LP. It holds Cognition Therapeutics’s shares valued at 0.

Cognition Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-219.68%

Trailing 12-Months

Asset Growth

-42.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cognition Therapeutics

Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of neurodegenerative diseases, such as Alzheimer's disease and other central nervous system disorders. The company's core product candidates are small molecule therapeutics designed to target synaptic dysfunction by modulating key protein interactions involved in the pathology of these diseases.

Cognition Therapeutics (CGTX) Earnings & Revenues

Historic Earnings Reports

CGTX Stock 12 Month Forecast

Average Price Target

$3.00

▲(80.72% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.8492307692307692,1.0284615384615385,1.2076923076923078,1.3869230769230771,1.5661538461538465,1.7453846153846153,1.9246153846153846,2.103846153846154,2.2830769230769232,2.4623076923076925,2.641538461538462,2.8207692307692307,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.8492307692307692,1.0284615384615385,1.2076923076923078,1.3869230769230771,1.5661538461538465,1.7453846153846153,1.9246153846153846,2.103846153846154,2.2830769230769232,2.4623076923076925,2.641538461538462,2.8207692307692307,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.8492307692307692,1.0284615384615385,1.2076923076923078,1.3869230769230771,1.5661538461538465,1.7453846153846153,1.9246153846153846,2.103846153846154,2.2830769230769232,2.4623076923076925,2.641538461538462,2.8207692307692307,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.67,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >